Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ADJUVANT LOCAL TREATMENT FOLLOWING CURATIVE TRANSURETHRAL RESECTION OF BLADDER-CARCINOMA
Autore:
OTTO T; GOEPEL M; RUBBEN H;
Indirizzi:
UNIV ESSEN GESAMTHSCH,UROL KLIN,HUFELANDSTR 55 W-4300 ESSEN 1 GERMANY
Titolo Testata:
Onkologie
fascicolo: 3, volume: 16, anno: 1993,
pagine: 158 - 162
SICI:
0378-584X(1993)16:3<158:ALTFCT>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
BACILLUS CALMETTE-GUERIN; TRANS-URETHRAL RESECTION; RANDOMIZED TRIAL; CANCER; DOXORUBICIN; MANAGEMENT; INTERFERON; THIOTEPA; THERAPY; TUMORS;
Keywords:
PROGNOSTIC PARAMETERS; INTRAVESICAL THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT IMMUNOTHERAPY; BLADDER CARCINOMA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
T. Otto et al., "ADJUVANT LOCAL TREATMENT FOLLOWING CURATIVE TRANSURETHRAL RESECTION OF BLADDER-CARCINOMA", Onkologie, 16(3), 1993, pp. 158-162

Abstract

The majority of bladder tumors are superficial (80%), classified as stage T(A) (62%) and T1 (38%), according to the criteria of the UICC. Transurethral resection is the initial treatment in bladder carcinomas. The major problem is to select those patients who are at risk for tumor recurrence or tumor progression and who may benefit from adjuvant treatment modalities. The analysis of prognostic factors emphasizes thefact that patients with T(A) or well-differentiated bladder carcinomabelong to a low-risk group and need no further intravesical therapy. On the other hand, T1 G2/3 bladder carcinoma and carcinoma in situ have to be considered as a high-risk group. We suggest that transurethralresection alone is not sufficient because these patients have an increased risk of local recurrence and progression. In treatment of bladder carcinoma it is reasonable to start intravesical chemotherapy (i.e. mitomycin or epirubicin or doxorubicin) or immunotherapy with BCG. So far there is no indication for clinical use of interferons in superficial bladder tumors. If the tumor persists, a second cycle of BCG treatment or intravesical chemotherapy can be added. However, the decision for cystectomy should be made not later than 3-4 months after the first TUR in high-risk bladder cancer patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 09:47:30